Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review

References

• [cited 2018 May 24]. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/
   Google Scholar
• Bhatt DL, Peterson ED, Harrington RA, et al.; CRUSADE Investigators. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009;30:1195–1202.
   PubMed Web of Science ®Google Scholar
• De Luca L, Di Pasquale G, Gonzini L, et al. Trends in management and outcome of patients with non-ST elevation acute coronary syndromes and peripheral arterial disease. Eur J Intern Med. 2019;59:70–76.
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Murray GD, Butcher I, et al.; Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208.
   PubMed Web of Science ®Google Scholar
• Aboyans V, Ricco J, Bartelink MEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) the task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816.
   PubMed Web of Science ®Google Scholar
• Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2017;135:e686–e725.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Alfonso F, Levine GN, et al. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 2018;72:2915–2931.
   PubMed Web of Science ®Google Scholar
• Hess CN, Hiatt WR. Antithrombotic therapy for peripheral artery disease in 2018. JAMA. 2018;319:2329–2330.
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–1206.
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Low LP, Tuta S, et al. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur Heart J. 2006;27:1861–1867.
   PubMed Web of Science ®Google Scholar
• Imori Y, Akasaka T, Ochiai T, et al. Co-existence of carotid artery disease, renal artery stenosis, and lower extremity peripheral arterial disease in patients with coronary artery disease. Am J Cardiol. 2014;113:30–35.
   PubMed Web of Science ®Google Scholar
• Hur DJ, Kizilgul M, Aung WW, et al. Frequency of coronary artery disease in patients undergoing peripheral artery disease surgery. Am J Cardiol. 2012;110:736–740.
   PubMed Web of Science ®Google Scholar
• Saw J, Bhatt DL, Moliterno DJ, et al. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol. 2006;48:1567–1572.
   PubMed Web of Science ®Google Scholar
• Burek KA, Sutton-Tyrrell K, Brooks MM, et al. Prognostic importance of lower extremity arterial disease in patients undergoing coronary revascularization in the bypass angioplasty revascularization investigation (BARI). J Am Coll Cardiol. 1999;34:716–721.
   PubMed Web of Science ®Google Scholar
• Jamieson WR, Janusz MT, Miyagishima RT, et al. Influence of ischemic heart disease on early and late mortality after surgery for peripheral occlusive vascular disease. Circulation. 1982;66:I92–I97.
   PubMed Web of Science ®Google Scholar
• Roger VL, Ballard DJ, Hallett JW Jr, et al. Influence of coronary artery disease on morbidity and mortality after abdominal aortic aneurysmectomy: a population-based study, 1971–1987. J Am Coll Cardiol. 1989;14:1245–1252.
   PubMed Web of Science ®Google Scholar
• Welten GM, Schouten O, Hoeks SE, et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol. 2008;51:1588–1596.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
   PubMed Web of Science ®Google Scholar
• Belch J, MacCuish A, Campbell I, et al.; Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group; Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Price JF, Stewart MC, et al. Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841–848.
   PubMed Web of Science ®Google Scholar
• Catalano M, Born G, Peto R; Critical Leg Ischaemia Prevention Study (CLIPS) Group. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007;261(3):276–284.
   PubMed Web of Science ®Google Scholar
• Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301:1909–1919.
   PubMed Web of Science ®Google Scholar
• Janzon L, Bergqvist D, Boberg J, et al. Prevention of Myocardial Infarction and Stroke in Patients With Intermittent Claudication; Effects of Ticlopidine. Results From STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med. 1990;5:301–308.
   Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339.
   PubMed Web of Science ®Google Scholar
• Chiarito M, Sans-Sanchez J, Cannata F, et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet. 2020;395:1487–1495.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982–1988.
   PubMed Web of Science ®Google Scholar
• Cacoub PP, Bhatt DL, Steg PG. et al.; CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30:192–201.
   PubMed Web of Science ®Google Scholar
• CASPAR Writing Committee. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52:825–833.
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–2166.
   PubMed Web of Science ®Google Scholar
• Secemsky EA, Yeh RW, Kereiakes DJ. et al.; Dual Antiplatelet Therapy Study Investigators. Extended duration dual antiplatelet therapy after coronary stenting among patients with peripheral arterial disease: a subanalysis of the dual antiplatelet therapy study. JACC Cardiovasc Interv. 2017;10:942–954.
   PubMed Web of Science ®Google Scholar
• Franzone A, Piccolo R, Gargiulo G, et al. Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: a subgroup analysis of the PRODIGY randomized clinical trial. JAMA Cardiol. 2016;1:795–803.
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation. 2010;122:394–403.
   PubMed Web of Science ®Google Scholar
• Ohno K, Tomizawa A, Mizuno M, et al. Prasugrel, a platelet P2Y12 receptor antagonist, improves abnormal gait in a novel murine model of thrombotic hindlimb ischemia. J Am Heart Assoc. 2016;5:e002889.
   PubMed Web of Science ®Google Scholar
• Danielak D, Karaźniewicz-Łada M, Główka F. Ticagrelor in modern cardiology - an up-to-date review of most important aspects of ticagrelor pharmacotherapy. Expert Opin Pharmacother. 2018;19:103–112.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
   PubMed Web of Science ®Google Scholar
• Patel MR, Becker RC, Wojdyla DM, et al. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO Trial. Eur J Prev Cardiol. 2015;22:734–742.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016;67:2719–2728.
   PubMed Web of Science ®Google Scholar
• Hiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376:32–40.
   PubMed Web of Science ®Google Scholar
• Gutierrez JA, Mulder H, Jones WS, et al. Polyvascular disease and risk of major adverse cardiovascular events in peripheral artery disease: a secondary analysis of the EUCLID trial. JAMA Network Open. 2018;1:e185239.
   PubMed Web of Science ®Google Scholar
• Magnani G, Bonaca MP, Braunwald E, et al. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. 2015 19;4:e001505.
   PubMed Web of Science ®Google Scholar
• Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20–33.
   PubMed Web of Science ®Google Scholar
• Jones WS, Tricoci P, Huang Z, et al. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER). Am Heart J. 2014;168:588–596.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Braunwald E, Bonaca MP, et al.; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404–1413.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°PTIMI 50. Circulation. 2013;127:1522–1529.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Gutierrez JA, Creager MA, et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis- thrombolysis in myocardial infarction 50 (TRA2°P-TIMI 50). Circulation. 2016;133:997–1005.
   PubMed Web of Science ®Google Scholar
• Qamar A, Morrow DA, Creager MA, et al. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: analysis from the TRA 2°P-TIMI 50 Trial. Vasc Med. 2020 Jan 30;25:124–132. [ Online ahead of print].
   PubMed Web of Science ®Google Scholar
• Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217–227.
   PubMed Web of Science ®Google Scholar
• Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch bypass oral anticoagulants or aspirin study): a randomised trial. Lancet. 2000;355:346–351.
   PubMed Web of Science ®Google Scholar
• Johnson WC, Williford WO; Department of Veterans Affairs Cooperative Study. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg. 2002;35:413–421.
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–1330.
   PubMed Web of Science ®Google Scholar
• Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:219–229.
   PubMed Web of Science ®Google Scholar
• Moll F, Baumgartner I, Jaff M, et al. Edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial. J Endovasc Ther. 2018;25:158–168.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382:1994–2004.
   PubMed Web of Science ®Google Scholar